NIH R01 · 2024
PROJECT SUMMARY Herpes simplex virus (HSV) keratitis is the leading cause of corneal ulcers and infection-associated blindness in the United States. The existing antiviral therapies for the topical management of ocular herpes infections include nucleoside analogs such as ganciclovir and trifluridine which need to be administered 5-8 times a day to control the infection. Hence, current topical therapies have patient adherence issues which impact therapeutic outcomes. In addition to the limited topical bioavailability, the emergence of drug resistance to acyclic nucleosides has necessitated the development of long-acting antiviral therapies for the topical treatment of ocular herpes…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.